Literature DB >> 19188663

Circulating clonotypic B cells in classic Hodgkin lymphoma.

Richard J Jones1, Christopher D Gocke, Yvette L Kasamon, Carole B Miller, Brandy Perkins, James P Barber, Milada S Vala, Jonathan M Gerber, Lan L Gellert, Mark Siedner, M Victor Lemas, Sarah Brennan, Richard F Ambinder, William Matsui.   

Abstract

Although Hodgkin and Reed-Sternberg (HRS) cells are B lymphoid cells, they are unlike any normal cells of that lineage. Moreover, the limited proliferative potential of HRS cells belies the clinical aggressiveness of Hodgkin lymphoma (HL). More than 20 years ago, the L428 HL cell line was reported to contain a small population of phenotypic B cells that appeared responsible for the continued generation of HRS cells. This observation, however, has never been corroborated, and such clonotypic B cells have never been documented in HL patients. We found that both the L428 and KM-H2 HL cell lines contained rare B-cell subpopulations responsible for the generation and maintenance of the predominant HRS cell population. The B cells within the HL cell lines expressed immunoglobulin light chain, the memory B-cell antigen CD27, and the stem cell marker aldehyde dehydrogenase (ALDH). Clonal CD27(+)ALDH(high) B cells, sharing immunoglobulin gene rearrangements with lymph node HRS cells, were also detected in the blood of most newly diagnosed HL patients regardless of stage. Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188663      PMCID: PMC2700327          DOI: 10.1182/blood-2008-11-189688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  Molecular pathogenesis of Hodgkin's lymphoma.

Authors:  Daniel Re; Ralf Küppers; Volker Diehl
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

2.  B-cell differentiation immunophenotypes in classical Hodgkin lymphomas.

Authors:  Maria Bai; Vassilios Panoulas; Alexandra Papoudou-Bai; Nikolaos Horianopoulos; Panagiotis Kitsoulis; Kalliopi Stefanaki; Dimitra Rontogianni; Niki John Agnantis; Panagiotis Kanavaros
Journal:  Leuk Lymphoma       Date:  2006-03

3.  Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.

Authors:  Alexey Ushmorov; Frank Leithäuser; Olena Sakk; Andreas Weinhaüsel; Sergey W Popov; Peter Möller; Thomas Wirth
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

Review 4.  Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.

Authors:  Maike Buettner; Axel Greiner; Athanasia Avramidou; Hans-Martin Jäck; Gerald Niedobitek
Journal:  Hematol Oncol       Date:  2005 Sep-Dec       Impact factor: 5.271

5.  Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease.

Authors:  A Carbone; A Gloghini; G Gaidano; S Franceschi; D Capello; H G Drexler; B Falini; R Dalla-Favera
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

Review 6.  Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.

Authors:  Andreas Bräuninger; Roland Schmitz; Dörte Bechtel; Christoph Renné; Martin-Leo Hansmann; Ralf Küppers
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

Review 7.  Pathobiology of classical Hodgkin lymphoma.

Authors:  Alexandar Tzankov; Stephan Dirnhofer
Journal:  Pathobiology       Date:  2006       Impact factor: 4.342

8.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Authors:  Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott A Kerns; Zhenping Zhu; Daniel Hicklin; Yan Wu; Jeffrey L Port; Nasser Altorki; Elisa R Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

9.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

Authors:  Anjli Kukreja; Aisha Hutchinson; Kavita Dhodapkar; Amitabha Mazumder; David Vesole; Revathi Angitapalli; Sundar Jagannath; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

Review 10.  Preparing the "soil": the premetastatic niche.

Authors:  Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

View more
  71 in total

Review 1.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

2.  A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.

Authors:  Chung-Gi Lee; Bikul Das; Tara L Lin; Chelsea Grimes; Xin Zhang; Tracey Lavezzi; Li Huang; John Cole; Lillian Yau; Li Li
Journal:  Br J Haematol       Date:  2012-04-18       Impact factor: 6.998

Review 3.  Anti-CD30 Antibodies for Hodgkin lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

Review 4.  Cancer stem cells: relevance to clinical transplantation.

Authors:  Gabriel Ghiaur; Jonathan M Gerber; William Matsui; Richard J Jones
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

5.  High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Authors:  Douglas E Gladstone; Javier Bolaños-Meade; Carol Ann Huff; Marianna Zahurak; Ian Flinn; Ivan Borrello; Leo Luznik; Ephraim Fuchs; Yvette Kasamon; William Matsui; Jonathan Powell; Hyam Levitsky; Robert A Brodsky; Richard Ambinder; Richard J Jones; Lode J Swinnen
Journal:  Leuk Lymphoma       Date:  2011-07-14

6.  LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates.

Authors:  Valérie Lajoie; Bruno Lemieux; Bassem Sawan; Daniel Lichtensztejn; Zelda Lichtensztejn; Raymund Wellinger; Sabine Mai; Hans Knecht
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 7.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

8.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

10.  Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Authors:  Mikhail Roshal; Brent L Wood; Jonathan R Fromm
Journal:  Adv Hematol       Date:  2010-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.